CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75.2% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Close

Trade BioNTech BNTX

Sell
 Buy

BioNTech live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

BioNTech news

Emma Rose 2025 Jul 03, 08:35

US Economy on Stagflation Watch: Apollo Global Management's Outlook

Ava Grace 2025 Jul 03, 08:35

AI Podcast: Fresh Insights on Fed Rate Cut Timing - News in a New Way

Sophia Claire 2025 Jul 03, 07:35

S&P 500 Earnings Season to Test Rally Amidst Dim Outlook

Sophia Claire 2025 Jul 03, 07:35

AI Podcast: Stock Market Melt-Up Potential? Examining the Bull Run

Noah Lee 2025 Jul 03, 07:35

AI Podcast: Does the Gold-Platinum Ratio Signal Stock Market Risk?

Latest news

Show more

Info

Spread

1.0982

Spread (%)

0.9763 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Tuesday

13:31 - 19:59

Monday

13:31-19:59

Wednesday

13:31-19:59

Thursday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

27719948288

Shares Outstanding

240395008

Earnings Date (Next)

0000-00-00

Div Yield

2022-06-17

Ex-Dividend Date

2022-06-02

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-3.76

Learn more about this instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Ghko B 2025 Jul 28, 16:00

VisionWave Stock (VWAV) Surges: What Drives the VWAV Stock Prices?

Stocks
Ghko B 2025 Jul 28, 16:00

Ethereum (ETH-USD) Eyes $10K: How to Trade Ethereum CFD?

Crypto
Ghko B 2025 Jul 28, 16:00

What Is Stellar (XLM): How to Trade Stellar (XLM) CFDs?

Crypto
Trustpilot